Dulaglutide
Semaglutide provides more weight loss, larger HbA1c reduction than dulaglutide in diabetes
Adults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan.
33% of adults with type 2 diabetes lost 5% or more of body weight with GLP-1 agonists
About one-third of adults who were prescribed a GLP-1 receptor agonist to treat type 2 diabetes lost at least 5% of their body weight at 72 weeks, according to findings from a real-world retrospective analysis.
Cases of acute cholecystitis linked to GLP-1 receptor agonist use in US
Researchers have found 36 cases of acute cholecystitis associated with the use of GLP-1 receptor agonists in the U.S., according to findings from the FDA Adverse Event Reporting System published in JAMA Internal Medicine.
Dulaglutide improves HbA1c for youths with type 2 diabetes without rise in BMI
NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to findings from a phase 3 trial.